Trial intelligence / Profile preview

Treatment of premalignant skin lesions with topical imiquimod and photodynamic therapy in organ-transplanted patients

2008-004044-36Phase 3Completed

Sponsor: Bispebjerg and Frederiksberg Hospital
Start: Jul 2008
Modality: Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, single-blind trial of imiquimod and methyl aminolevulinate in actinic keratosis (AK) and Wart (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Reduction in number of treated viral warts and actinic keratoses. Started Jul 2008; status: completed.

Drugs

imiquimodmethyl aminolevulinate

Conditions

actinic keratosis (AK)Wart

Beyond the preview

Go deeper on 2008-004044-36.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-004044-36.